Turning Point Therapeutics, Inc. Research and Development Expense
Turning Point Therapeutics, Inc. reported Research and Development Expense of $86.79 million for the 3-month period ending 2022-06-30, per its 10-Q filed 2022-08-08.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2022-08-08
- Turning Point Therapeutics, Inc. research and development expense for the quarter ending 2022-06-30 was $86.79M, a 94.37% increase year-over-year.
- Turning Point Therapeutics, Inc. research and development expense for the quarter ending 2022-03-31 was $55.05M, a 33.41% increase year-over-year.
- Turning Point Therapeutics, Inc. research and development expense for the quarter ending 2021-12-31 was $58.18M, a 69.74% increase year-over-year.
- Turning Point Therapeutics, Inc. research and development expense for the quarter ending 2021-09-30 was $48.89M, a 51.77% increase year-over-year.
- Turning Point Therapeutics, Inc. research and development expense for fiscal 2021 was $192.98M, a 70.16% increase from fiscal 2020.
- Turning Point Therapeutics, Inc. research and development expense for fiscal 2020 was $113.41M, a 95.73% increase from fiscal 2019.
- Turning Point Therapeutics, Inc. research and development expense for fiscal 2019 was $57.94M, a 175.11% increase from fiscal 2018.
- Turning Point Therapeutics, Inc. research and development expense for fiscal 2018 was $21.06M, a 38.19% increase from fiscal 2017.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2022-06-30 | $86.79M 10-Q · filed 2022-08-08 | $141.84M 10-Q · filed 2022-08-08 | $200.01M derived: sum of 3 quarters · filed 2022-08-08 | $248.90M derived: sum of 4 quarters · filed 2022-08-08 |
| 2022-03-31 | $55.05M 10-Q · filed 2022-05-10 | $113.23M derived: sum of 2 quarters · filed 2022-05-10 | $162.12M derived: sum of 3 quarters · filed 2022-05-10 | $206.77M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-12-31 | $58.18M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $107.07M derived: sum of 2 quarters · filed 2022-02-28 | $151.72M derived: sum of 3 quarters · filed 2022-08-08 | $192.98M 10-K · filed 2022-02-28 |
| 2021-09-30 | $48.89M 10-Q · filed 2021-11-09 | $93.54M derived: sum of 2 quarters · filed 2022-08-08 | $134.80M 10-Q · filed 2021-11-09 | $169.08M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-06-30 | $44.65M 10-Q · filed 2022-08-08 | $85.91M 10-Q · filed 2022-08-08 | $120.19M derived: sum of 3 quarters · filed 2022-08-08 | $152.40M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $41.26M 10-Q · filed 2022-05-10 | $75.54M derived: sum of 2 quarters · filed 2022-05-10 | $107.75M derived: sum of 3 quarters · filed 2022-05-10 | $131.91M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $34.27M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $66.49M derived: sum of 2 quarters · filed 2022-02-28 | $90.64M derived: sum of 3 quarters · filed 2022-02-28 | $113.41M 10-K · filed 2022-02-28 |
| 2020-09-30 | $32.21M 10-Q · filed 2021-11-09 | $56.37M derived: sum of 2 quarters · filed 2021-11-09 | $79.14M 10-Q · filed 2021-11-09 | $96.28M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $24.15M 10-Q · filed 2021-08-09 | $46.92M 10-Q · filed 2021-08-09 | $64.06M derived: sum of 3 quarters · filed 2022-02-28 | $80.70M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $22.77M 10-Q · filed 2021-05-05 | $39.91M derived: sum of 2 quarters · filed 2022-02-28 | $56.55M derived: sum of 3 quarters · filed 2022-02-28 | $70.26M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $17.14M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $33.78M derived: sum of 2 quarters · filed 2022-02-28 | $47.49M derived: sum of 3 quarters · filed 2022-02-28 | $57.94M 10-K · filed 2022-02-28 |
| 2019-09-30 | $16.64M 10-Q · filed 2020-11-12 | $30.35M derived: sum of 2 quarters · filed 2020-11-12 | $40.80M 10-Q · filed 2020-11-12 | $48.02M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $13.71M 10-Q · filed 2020-08-10 | $24.16M 10-Q · filed 2020-08-10 | $31.38M derived: sum of 3 quarters · filed 2021-03-01 | $36.51M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $10.45M 10-Q · filed 2020-05-12 | $17.67M derived: sum of 2 quarters · filed 2021-03-01 | $22.80M derived: sum of 3 quarters · filed 2021-03-01 | $27.17M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $7.22M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $12.35M derived: sum of 2 quarters · filed 2021-03-01 | $16.72M derived: sum of 3 quarters · filed 2021-03-01 | $21.06M 10-K · filed 2021-03-01 |
| 2018-09-30 | $5.13M 10-Q · filed 2019-11-04 | $9.50M derived: sum of 2 quarters · filed 2019-11-04 | $13.84M 10-Q · filed 2019-11-04 | |
| 2018-06-30 | $4.37M 10-Q · filed 2019-08-06 | $8.71M 10-Q · filed 2019-08-06 | ||
| 2018-03-31 | $4.34M 10-Q · filed 2019-05-31 | |||
| 2017-12-31 | $15.24M 10-K · filed 2020-03-18 |